日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Newsmakers

Key role seen in year ahead for Chinese vaccines

By ANGUS MCNEICE in London | China Daily Global | Updated: 2022-02-10 09:13
Share
Share - WeChat
A health worker inoculates a man with the Chinese Sinopharm vaccine during a door-to-door COVID-19 vaccination drive in Karachi, Pakistan, on Feb 2. RIZWAN TABASSUM/AFP

Sinovac, Sinopharm expected to be among top global distributors in fight against COVID

Chinese vaccines are set to play a crucial role in fighting the COVID-19 pandemic in 2022, with new analysis pointing to the quality and quantity expected this year.

Under projections provided to China Daily by London-based science consultancy Airfinity, Chinese pharmaceutical companies Sinovac and Sinopharm are expected to be the third- and fourth-largest providers of COVID-19 vaccines this year.

Airfinity predicts that Sinovac will contribute 1.88 billion vaccines this year and Sinopharm will distribute 1.85 billion. By volume, both companies are expected to contribute more than vaccine powerhouses AstraZeneca (1.75 billion), Moderna (1.62 billion) and Johnson & Johnson (1.34 billion).

Pfizer will lead vaccine production this year, contributing 4.11 billion vaccine doses, while Novavax will emerge as a major player in global treatment production, contributing 2.44 billion doses, according to Airfinity's projections.

The consultancy also predicted that 19 major manufacturers will contribute a combined 16.71 billion doses this year. Of these, 3.8 billion, or 23 percent, will come from Chinese manufacturers, which also include CanSino Biologics (73.5 million).

Meanwhile, a new study from Oxford University found that the CoronaVac vaccine from Sinovac can be effectively boosted by a third vaccine of the same or different type. This is seen as a crucial feature of any successful vaccine at this point in the pandemic, as protection among the vaccinated begins to wane and new variants emerge.

In a study of 1,240 participants in Sao Paulo, Brazil, researchers established that a booster dose of any of the Pfizer, AstraZeneca, Johnson & Johnson or CoronaVac vaccines induces a significant increase in antibody levels in those who have previously received two doses of CoronaVac.

The results, which were published this week in a peer-reviewed paper in the medical journal The Lancet, showed that a heterologous-or mixed-vaccine schedule provoked the strongest immune reaction, including against the Delta and Omicron variants. The study also found that the mixed schedule with the strongest response consisted of two CoronaVac shots followed by a Pfizer booster.

"The new data presented here show the extraordinary response to a third dose of coronavirus vaccines in a heterologous vaccine schedule," said Sue Ann Costa Clemens, an infectious diseases specialist at the Oxford Vaccine Group and lead author of the paper. "These data will also guide other low- and middle-income countries in setting up the most optimal and affordable booster programs."

Because the CoronaVac vaccine is easy to transport and store, it is seen as an attractive option for distribution in remote and less-developed regions.

Meanwhile, another study released this month showed how effective the Sinovac vaccine is in getting outbreaks under control and communities in the developing world back on track.

Two years ago, health authorities in Colombia sent a research team to Mitu, an Indigenous community deep in the Amazon Basin, having received word of an unusually high infection rate for COVID-19.

The team of scientists led by the University of Cordoba in Colombia confirmed these suspicions. More than half of people tested had antibodies for the novel coronavirus, translating to one of the highest community seropositivity levels in the world.

Then, in February last year, the Colombian Ministry of Health and Social Protection received its first shipment of CoronaVac doses and immediately sent them to towns on the border with Brazil, including Mitu, in order to set up an inoculation blockade to prevent the spread of a worrisome new variant into Colombia.

Authorities provided the vaccine to 99.9 percent of the adult urban population in Mitu, totaling 7,849 people, and Cordoba researchers monitored the effectiveness of the CoronaVac injection.

The results, published this month, revealed a resounding success. CoronaVac showed 99.9 percent effectiveness at preventing severe infection, and just one death was reported. In Mitu, CoronaVac reduced the mortality rate from 2.2 percent in 2020 to 0.22 percent in 2021.

The Colombian health ministry selected CoronaVac for use in remote communities in part because it does not require ultracold refrigeration.

"This vaccination strategy could be relevant to mitigate the spread of COVID-19 in small and remote communities in Latin America," according to the study authors, who were led by University of Cordoba microbiologist Salim Mattar.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 91麻豆蜜桃一区二区三区 | 久久精品免费视频观看 | 国内精品久久久久影院老司 | 一级特黄aaa免费 | 99精品久久| 黄视频网站在线 | 国产三级在线精品男人的天堂 | 午夜激情视频 | 欧美性生活区 | 亚洲精品三级 | 免费高清seyeye在线视频观看 | 久久一本日韩精品中文字幕屁孩 | 日本色播 | 成人免费网址在线 | 男女爽爽无遮挡午夜动态图 | 国产a精品三级 | 亚洲成av人片在线观看 | 国产精品99久久 | 国产精品视频免费 | 久久久久国产精品一区 | 国产色网址 | 伊人亚洲| 日本高清动作片www网站免费 | 狠狠干av| 亚洲嗯啊 | 欧美日韩国产在线 | 五月婷六月婷婷 | 一级黄片毛片 | 在线观看av网站永久 | 久久久久国产精品 | 91精品一区二区三区久久久久久 | 欧美在线观看一区 | 99久久99久久精品免费看蜜桃 | 久操热久操 | 在线不卡视频 | 午夜av成人 | 1级a的观看视频 | 激情网五月天 | 成人免费视频网址 | 毛片网站在线 | 三级 在线播放 |